Skip to main
ABT

Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Labs (ABT) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 45%
Buy 55%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Abbott Laboratories is predicted to have a strong future outlook due to its strong medical device portfolio, growth strategies, and international expansion in high-growth areas. The company has shown a commitment to sustainability and has a positive impact on their stock price, expecting continued growth in the second half of the year with approval for new devices and clinical trials. Despite some challenges in the Chinese market and currency headwinds, ABT has a strong pipeline of new products and has beaten expectations in Q2, leading to a positive outlook for the company's future.

Bears say

Abbott Laboratories is a diversified healthcare company with a focus on cardiovascular and diabetes devices, nutritional products, and diagnostic equipment. While the company's international exposure provides potential for growth, its reliance on the diabetes care segment and potential competition in key markets present risks to its long-term outlook. Additionally, with a projected slowdown in diabetes sales, adjusted estimates and a potential resurgence of COVID-19, the company may face challenges in achieving its financial targets.

Abbott Labs (ABT) has been analyzed by 20 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 55% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abbott Labs (ABT) Forecast

Analysts have given Abbott Labs (ABT) a Buy based on their latest research and market trends.

According to 20 analysts, Abbott Labs (ABT) has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $123.35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $123.35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abbott Labs (ABT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.